TY - JOUR
T1 - Head and neck squamous cell carcinoma transcriptome analysis by comprehensive validated differential display
AU - Carles, A
AU - Millon, R
AU - Cromer, A
AU - Ganguli, G
AU - Lemaire, F
AU - Young, Julia Caitlin
AU - Wasylyk, C
AU - Muller, Daniele
AU - Schultz, I
AU - Rabouel, Y
AU - Dembele, D
AU - Zhao, C
AU - Marchal, P
AU - Ducray, C
AU - Bracco, L
AU - Abecassis, J
AU - Poch, O
AU - Wasylyk, B
PY - 2006
Y1 - 2006
N2 - Head and neck squamous cell carcinoma (HNSCC) is common worldwide and is associated with a poor rate of survival. Identification of new markers and therapeutic targets, and understanding the complex transformation process, will require a comprehensive description of genome expression, that can only be achieved by combining different methodologies. We report here the HNSCC transcriptome that was determined by exhaustive differential display (DD) analysis coupled with validation by different methods on the same patient samples. The resulting 820 nonredundant sequences were analysed by high throughput bioinformatics analysis. Human proteins were identified for 73 (596) of the DD sequences. A large proportion (>50 ) of the remaining unassigned sequences match ESTs (expressed sequence tags) from human tumours. For the functionally annotated proteins, there is significant enrichment for relevant biological processes, including cell motility, protein biosynthesis, stress and immune responses, cell death, cell cycle, cell proliferation and/or maintenance and transport. Three of the novel proteins (TMEM16A, PHLDB2 and ARHGAP21) were analysed further to show that they have the potential to be developed as therapeutic targets.
AB - Head and neck squamous cell carcinoma (HNSCC) is common worldwide and is associated with a poor rate of survival. Identification of new markers and therapeutic targets, and understanding the complex transformation process, will require a comprehensive description of genome expression, that can only be achieved by combining different methodologies. We report here the HNSCC transcriptome that was determined by exhaustive differential display (DD) analysis coupled with validation by different methods on the same patient samples. The resulting 820 nonredundant sequences were analysed by high throughput bioinformatics analysis. Human proteins were identified for 73 (596) of the DD sequences. A large proportion (>50 ) of the remaining unassigned sequences match ESTs (expressed sequence tags) from human tumours. For the functionally annotated proteins, there is significant enrichment for relevant biological processes, including cell motility, protein biosynthesis, stress and immune responses, cell death, cell cycle, cell proliferation and/or maintenance and transport. Three of the novel proteins (TMEM16A, PHLDB2 and ARHGAP21) were analysed further to show that they have the potential to be developed as therapeutic targets.
UR - http://www.nature.com/onc/journal/v25/n12/pdf/1209203a.pdf
U2 - 10.1038/sj.onc.1209203
DO - 10.1038/sj.onc.1209203
M3 - Article
SN - 0950-9232
VL - 25
SP - 1821
EP - 1831
JO - Oncogene
JF - Oncogene
IS - 12
ER -